Barclays on Gilead Sciences (GILD): 'Modest positive read-through for Trodelvy positioning in 2L+ HR/Her2- breast cancer'
Tweet Send to a Friend
Barclays analyst Carter Gould reiterated an Equalweight rating and $76.00 price target on Gilead Sciences (NASDAQ: GILD).The analyst comments "AstraZeneca ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
